Real-World Data
How Is Your Organization Currently Leveraging Real-World Data/Evidence and What Uses Do You Anticipate in the Future?
Pharma's Almanac
PAO-09-23-RT-01Sep 15, 2023
Industry Wisdom
What Piece of Conventional Industry Wisdom Do You Think is Misguided, Outdated, or Just Plain Wrong?
Pharma's Almanac
PAO-09-23-RT-02Sep 15, 2023
Roundtable: Artificial Intelligence
In what areas of pharma/biopharma are you most excited to see increased adoption of artificial intelligence (AI) and machine learning?
Pharma's Almanac
PAO-07-23-RT-01Jul 21, 2023
Combining RNA Splicing and AI Technologies to Accelerate Drug Discovery and Development
Martin Akerman, Ph.D.
Envisagenics
PAO-02-23-CL-08Apr 12, 2023
Life Science Industrials
Life Science Industrials Are Key to the Growth of the Biopharma Industry
Reinhard Vogt
Dynamk Capital
PAO-07-022-CL-05Aug 04, 2022
mRNA Manufacturing
Vernal Biosciences Raises $21 Million to Accelerate mRNA Manufacturing Growth
Vernal Biosciences
PR-M06-22-01-351Jun 02, 2022
Seed Funding
Bionter AG secures $3 Million in Series Seed Financing Led by Dynamk Capital
Bionter AG
PR-M04-22-13Apr 27, 2022
Cell and Gene Therapy Technology
Advancing Technologies in Cell and Gene Therapy
Gustavo Mahler, Ph.D.
Dynamk Capital
PAO-04-22-R250-09Apr 05, 2022
Life Science Industrials
The Potential of Life Science Industrials
Daniella Kranjac
Dynamk Capital
PAO-01-22-R250-05Jan 26, 2022
Life Science Industrials
Filling Industry Gaps and Driving Innovation with Life Science Industrials
Reinhard Vogt; Sebastien Latapie
Dynamk Capital
PAO-11-21-CL-01Nov 03, 2021
Stem Cells
Curi Bio Raises $6M Series A Financing Round for iPSC-derived Predictive Platforms
Curi Bio
PR-M03-21-004-1062Mar 18, 2021
The Future of Healthcare
How Does Dynamk Capital Envision the Future of the Pharma/Biopharma Industry?
Dynamk Capital
PAP-Q4-20-RT2-013Dec 09, 2020
Financing
Lucid Scientific Secures $3 Million in Series Seed Financing Led by Dynamk Capital
Lucid Scientific
PR-M10-20-03Oct 03, 2020
Organ-on-a-Chip
Organ-on-a-Chip Technology Aims to Disrupt Traditional Drug Testing Models
Gustavo Mahler, Ph.D.; Jessica Davis
Dynamk Capital
PAP-Q3-20-CL-014Sep 29, 2020
The Future of Healthcare
How Is Dynamk Capital Facing the Future of Healthcare?
Dynamk Capital
PAP-Q3-20-RT2-013Sep 29, 2020
Leadership
Dr. Gustavo Mahler Now a General Partner at Dynamk Capital
Dynamk Capital
PR-M04-20-NI-013-1618Apr 07, 2020
Strategic Partnership
Facilitating the Commercialization of Disruptive Industrial Life Science Technologies
Gustavo Mahler, Ph.D.; Daniella Kranjac
Dynamk Capital
PAP-Q1-20-CL-031Mar 19, 2020